Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial.

Matthew P GilbertJoan SkellyAdrian F HernandezJennifer B GreenKonstantin A KrychtiukChristopher B GrangerLawrence A LeiterJohn Joseph Valentine McMurrayStefano Del PratoRichard E Pratley

Published in: Diabetes, obesity & metabolism (2024)

This post hoc analysis adds to the body of literature showing that glucagon-like peptide 1 receptor agonists added to standard type 2 diabetes therapy safely reduce the incidence of cardiovascular events in older adults with established cardiovascular disease. In this analysis, the risk-benefit profile was similar between younger and older age groups treated with albiglutide.

Keyphrases

cardiovascular events
cardiovascular disease
type diabetes
physical activity
coronary artery disease
community dwelling
middle aged
systematic review
risk factors
cardiovascular risk factors
stem cells
newly diagnosed
skeletal muscle
metabolic syndrome
mesenchymal stem cells
smoking cessation
data analysis